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background
 
Neurocysticercosis is the main cause of adult-onset seizures in the developing world.
Whether therapy with antiparasitic agents results in improved seizure control has been
questioned because of the lack of adequate, controlled studies.
 
methods
 
We conducted a double-blind, placebo-controlled trial in which 120 patients who had
living cysticerci in the brain and seizures treated with antiepileptic drugs were randomly
assigned to receive either 800 mg of albendazole per day and 6 mg of dexamethasone
per day for 10 days (60 patients) or two placebos (60 patients). The patients were followed
for 30 months or until they had been seizure-free for 6 months after the doses of the an-
tiepileptic drugs had been tapered. The efficacy of treatment was measured as the de-
crease in the number of seizures after treatment. 
 
results
 
In the albendazole group, there was a 46 percent reduction in the number of seizures
(95 percent confidence interval, ¡74 to 83 percent) during months 2 to 30 after treat-
ment. This reduction, which was not statistically significant, was composed of a non-
significant reduction of 41 percent in the number of partial seizures (95 percent confi-
dence interval, ¡124 to 84 percent) and a significant 67 percent reduction in the number
of seizures with generalization (95 percent confidence interval, 20 to 86 percent). Most
of the difference in the number of partial seizures was attributable to a few patients who
had many seizures during follow-up. The proportions of patients who had partial sei-
zures during follow-up were similar in the two groups (19 of 57 in the albendazole
group and 16 of 59 in the placebo group), but the patients in the placebo group had a
greater tendency to have seizures with generalization (22 of 59, vs. 13 of 57 in the al-
bendazole group; risk ratio, 1.63; 95 percent confidence interval, 0.91 to 2.92). More of
the intracranial cystic lesions resolved in the albendazole group than in the placebo
group. With the sole exception of abdominal pain, side effects did not differ signifi-
cantly between the two groups. 
 
conclusions
 
In patients with seizures due to viable parenchymal cysts, antiparasitic therapy decreas-
es the burden of parasites and is safe and effective, at least in reducing the number of sei-
zures with generalization.
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n the developing world, neurocys-
 
ticercosis — infection of the central nervous
system with 
 
Taenia solium
 
 larvae — is the sin-
gle most common cause of acquired epilepsy.
 
1
 
 In
Latin America alone, it is estimated that more than
400,000 persons have neurologic symptoms due to
neurocysticercosis.
 
2
 
 The disease has also become
increasingly recognized in industrialized countries,
because of immigration from countries where the
infection is endemic and improved neuroimaging
and serologic means of diagnosis.
 
3
 
 Recently, neu-
rocysticercosis was found in 10 percent of patients
with seizures who presented to an emergency de-
partment in Los Angeles and 6 percent of such pa-
tients in New Mexico.
 
4
 
In the brain, 
 
T. solium
 
 larvae survive for a poorly
defined period, estimated to be several years,
 
5
 
 and
then degenerate into granulomas that in turn be-
come calcified scars (Fig. 1). Infestation of the ce-
rebral parenchyma is usually manifested as seizures
and is more frequent than extraparenchymal infes-
tation (involving the ventricles, basal cisterns, or
subarachnoid space).
 
6,7
 
 The prognosis and man-
agement differ considerably according to the loca-
tion, life-cycle stage, and number of parasites in the
central nervous system.
 
8
 
Albendazole is the antiparasitic drug of choice
 
8,9
 
;
it kills cerebral cysts in humans and in pigs.
 
9,10
 
 No
double-blind, placebo-controlled trials have yet
been performed to test whether the course of sei-
zures associated with viable parenchymal cysts is
improved with albendazole therapy.
 
11-13
 
 Three ma-
jor arguments against the use of antiparasitic ther-
apy in neurocysticercosis have been raised: first,
that there are immediate risks because of neurologic
symptoms due to the acute inflammation that re-
sults from the death of the cysts
 
14-17
 
; second, that
the long-term prognosis of the underlying seizure
disorder may worsen because of increased scarring
due to the acute inflammation
 
18,19
 
; and third, that
treatment is unnecessary since most cysts die by
themselves within a short period.
 
13,20,21
 
 We evalu-
ated the effects of albendazole therapy on seizures in
patients with intraparenchymal neurocysticercosis.
 
patients
 
Between January 1997 and March 1999, 120 adult
Peruvian patients with viable parenchymal cysts
were consecutively enrolled after their written in-
formed consent had been obtained. Criteria for in-
clusion were the presence of well-delimited, round,
hypodense cysts on cerebral computed tomogra-
phy (CT), serologic confirmation of 
 
T. solium
 
 infec-
tion by enzyme-linked immunoelectrotransfer blot
assay,
 
22
 
 and a history of one or more spontaneous
seizures within the previous 6 months but less than
10 years in duration. Seizures were diagnosed and
categorized according to standard criteria from the
International League against Epilepsy.
 
23,24
 
 Patients
were excluded from the study if they had primary
generalized seizures, a history of antiparasitic treat-
ment, more than 20 cysts on CT, evidence on CT of
other diseases not attributable to cysticercosis, mod-
erate or severe intracranial hypertension, status ep-
ilepticus, focal neurologic deficits, unstable vital
signs, or an impending risk of death. Patients were
also excluded if they were pregnant. The study and
the written consent form were approved by the in-
stitutional review boards of the Johns Hopkins Uni-
versity Bloomberg School of Public Health in Bal-
timore and the Universidad Peruana Cayetano
Heredia in Lima.
 
stage of parasites
 
This study included patients with at least one viable
cyst, defined as a hypodense vesicle visible on CT.
Cysts with signs of inflammation (edema or con-
trast enhancement) were included only if CT clearly
showed that they had liquid contents (as indicated
by a density on imaging similar to that of cerebro-
spinal fluid) and if the presence of liquid was con-
firmed by magnetic resonance imaging (MRI) (as a
hyperintense signal on T
 
2
 
-weighted imaging and
a hypointense signal on fluid-attenuation inversion
recovery protocols). Lesions with inflammation
were considered to be a separate subgroup during
analysis, because such lesions represent parasites
that have already been attacked by the host’s im-
mune system. Parasites that had already degener-
ated at the time of a patient’s enrollment (as indicat-
ed by the presence of lesions surrounded by edema
and showing abnormal enhancement but without
discernible liquid contents) were not considered in
the evaluation of treatment efficacy.
 
examination and treatment
 
All the consenting patients provided a complete
history and underwent physical examination, elec-
troencephalography, MRI of the brain, plain-film
radiographs of the chest, stool examinations, and
hematologic studies, including measurements of
glucose and creatinine levels and liver-function tests.
i
methods
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MRI was used to improve the precision of the imag-
ing diagnosis in terms of the number of lesions and
their stage and thus to improve the base-line as-
sessment and allow better follow-up comparisons.
Eligible patients were then enrolled and assigned a
study number. Random assignment of the patients
to one of the two study groups was performed (in
Lima, by a biostatistician not otherwise involved in
the study) in blocks of six according to a preestab-
lished list taken from a random-numbers table.
Patients were admitted to the hospital and re-
ceived either 400 mg of albendazole given orally ev-
ery 12 hours and 2 mg of dexamethasone given
orally every 8 hours for 10 days or two placebos of
similar appearance at the same intervals and for the
same period. All drugs and placebos were adminis-
tered by the study personnel, who received them in
sealed, opaque, sequentially numbered envelopes.
Adequate antiepileptic-drug therapy (one first-
line antiepileptic drug given at internationally ac-
 
Figure 1. Stages of Neurocysticercosis Lesions in the Human Brain.
 
Contrast-enhanced T
 
1
 
-weighted MRI scans show a viable cyst (Panel A), a cyst with the initial signs of inflammation 
(Panel B), and a degenerating cyst (Panel C). A CT image obtained without the use of contrast material shows calcified 
parasites (Panel D).
A B
C D
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cepted doses and monitored by measuring its se-
rum level),
 
25
 
 as prescribed by the patients’ attend-
ing neurologist, was provided free of charge. If they
were not already receiving treatment, enrolling pa-
tients were given phenytoin. If seizure control was
poor (i.e., if more than two seizures occurred dur-
ing a six-month period), patients were interviewed,
the blood level of their antiepileptic drug was mea-
sured, and the dosage was adjusted if needed. If
seizures still remained poorly controlled, therapy
was switched to a different antiepileptic drug. After
one seizure-free year, the drug dosage was tapered
over a two-month period and stopped. Patients left
the study if they had had six seizure-free months af-
ter the tapering of their antiepileptic drug.
Before discharge, all patients received informa-
tion regarding indications for therapy, a supply of
antiepileptic drugs, and a diary to record any symp-
toms compatible with a seizure. Patients were in-
structed to visit the clinic or report by telephone if
any event compatible with a seizure occurred. Fol-
low-up visits were planned 30, 60, and 90 days after
the end of treatment and every 3 months thereafter
until 30 months after treatment. At the end of the
follow-up period, patients still having seizures were
referred to the routine care of the hospital’s seizure
clinic.
Repeated MRI examination was scheduled to
take place 6 months after treatment and CT exami-
nations to take place 12 and 24 months after treat-
ment. Follow-up scans were read by a neuroradiol-
ogist who was unaware of the patients’ treatment
assignments and who was instructed to report any
increase in the number of lesions, any increase in
the size of a lesion (by more than 1 cm in diameter),
or the development of hydrocephalus.
A data safety and monitoring board composed
of two neurologists and one biostatistician met ev-
ery six months to examine all adverse events and re-
view the progress of the study. Two of the authors
analyzed the data.
 
statistical analysis
 
The sample size of 120 patients was chosen to pro-
vide the study with 90 percent power to distinguish
between a 30-month cumulative incidence of sei-
zure of 70 percent in the placebo group and 35 per-
cent in the albendazole group, with a 5 percent two-
sided type I error and 20 percent loss to follow-up.
At the initial meeting of the data safety and moni-
toring board, before any patients were enrolled, it
was decided that the primary outcome would be the
number of seizures with generalization (including
generalized seizures, complex partial seizures and
partial seizures with secondary generalization), be-
cause of their effect on the life of the patients. Partial
seizures were analyzed separately. Seizures were an-
alyzed both with respect to the entire study period
and with respect to each of several relevant periods
within it: the first month after discharge from the
hospital, the first year of follow-up (during antiep-
ileptic-drug therapy), and the first six months after
the antiepileptic therapy had begun to be tapered.
The decision to analyze data from the first month
separately was made in the early stages of the tri-
al, before any data analysis, because the rate of sei-
zures can increase after corticosteroid tapering.
 
26
 
Since data from patients who remained seizure-free
for 6 months after drug tapering were censored
from further analysis (as early as 18 months after
the start of treatment, resulting in variable follow-
up periods), we also analyzed results censored as
of 18 months, so that any follow-up bias would be
eliminated.
In any given observation period, a Poisson re-
gression model was fitted to the number of seizures
of the specified type experienced by each patient,
with a dichotomous variable used for the randomly
assigned treatment regimen. Within-person corre-
lation was accounted for with the use of a quasilike-
lihood approach, through the calculation of Pear-
son’s scale parameter. This population-averaged
model, which reproduces the raw rates, was coded
before seizure distributions were examined; no oth-
er types of regression models were fitted. In adjust-
ed analysis, the Poisson regression models con-
tained variables that remained at a significance level
of P<0.20 after a backward-selection procedure.
The variables, data for which were obtained at base
line, were age, sex, number of viable cysts, prior to-
tal number of seizures, prior number of general-
ized seizures, and prior duration of illness. The lat-
ter four variables were rendered dichotomous by
comparing the highest quartiles with all the other
quartiles. Efficacy was calculated as 100¬[1¡the
rate in the albendazole group÷the rate in the pla-
cebo group]; a negative value indicated that the rate
of seizures in the albendazole group was greater
than that in the placebo group. In a separate set of
Poisson models, we modeled seizure rates as a func-
tion of whether a patient was free of active lesions
at his or her six-month MRI, but without incorpo-
rating any treatment variable. Bivariate analysis was
based on the chi-square test, two-tailed Fisher’s ex-
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act test, or Mann–Whitney test. An interim analysis
for efficacy was performed when there were 28 pa-
tients with at least one seizure with generalization;
the trigger point at which stopping the trial could
be considered was an alpha level of 0.0035. All re-
ported P values are two-sided. Analyses were carried
out with the use of SAS software (version 8).
Of 139 patients who underwent MRI to assess their
eligibility for the study, 19 were not enrolled, for the
following reasons: the presence of only degenerat-
ing cysts (1 such cyst in 8 patients and more than
1 in 2), the presence of more than 20 viable cysts (in
6 patients), the existence of other diseases (in 2 pa-
tients), and the request for open treatment (in 1 pa-
tient). A total of 120 patients were included in the
study and were randomly assigned to a study group
(60 patients to the albendazole group and 60 pa-
tients to the placebo group). The study cohort in-
cluded 61 male patients and 59 female patients;
their mean (
 
±
 
SD) age was 33
 
±
 
13 years (range, 16 to
65). There were no statistically significant differ-
ences between the two treatment groups in terms
of base-line characteristics (Table 1).
Four patients did not receive the study drugs:
two did not return to the hospital for admission,
one refused to take an antiepileptic drug, and in one
a brain-stem cyst was found on MRI and the attend-
ing neurologists decided not to expose her to anti-
parasitic therapy. Thus, 116 patients (57 assigned to
albendazole and 59 to placebo) received the study
medication and were the subject of the analyses. All
the patients who initiated treatment received the
complete 10-day dosage.
Seven patients from each group were lost to fol-
low-up. Two additional patients were excluded from
follow-up analysis: one requested albendazole treat-
ment, and the other bought and ingested 400 mg of
albendazole to treat intestinal worms.
Twelve patients, six from each group, were re-
admitted to the hospital because of seizures. Poten-
tial causes were identified in nine: poor compliance
with their antiepileptic-drug regimen (in five), cor-
ticosteroid tapering (in two), hyperemesis of preg-
nancy (in one), and alcohol ingestion (in one).
 
side effects
 
The proportion of patients who had seizures, head-
aches, or other neurologic symptoms during treat-
ment was similar in the two study groups (Table 2).
Non-neurologic side effects included abdominal
pain, nausea, and diarrhea. In one patient, the liver-
enzyme levels were higher than normal at the 18-
month evaluation, but they became normal after her
dose of phenytoin was reduced.
Adverse events occurred in three patients, all in
the placebo group. One patient became pregnant
and was later readmitted (as noted above) for con-
trol of seizures, which were probably related to
hyperemesis of pregnancy (nausea, vomiting, and
dehydration). One patient returned one day after
discharge from the hospital with blurred vision and
a left-sided motor deficit, caused by bleeding from a
brain-stem arteriovenous malformation (which had
been missed in the enrollment evaluation). His con-
dition was stabilized, but right hemiparesis and
tremor persisted one year later. One patient was di-
agnosed as having gastric cancer and died during
follow-up.
 
seizures during follow-up
 
During the overall follow-up period (months 2 to
30), patients in the albendazole group had 46 per-
results
 
Table 1. Characteristics of the Patients at Base Line.
Characteristic
Albendazole
(N=60)
Placebo
(N=60) P Value
 
Age (yr)
Median
Range
31
17–65
29
16–65
0.25
Male sex (no.) 29 32 0.71
Number of cysts
Total
Median
Interquartile range
Without inflammation
Median
Interquartile range
With inflammation
Median
Interquartile range
3
1–9
1
0–7
1
0–1
2
1–8
2
1–7
1
0–1
0.34
0.37
0.23
No. of calcifications
Median
Interquartile range
0
0–2
0
0–3
0.45
Duration of illness (mo)
Median
Interquartile range
12
1–48
12
3–48
0.35
No. of seizures before study entry
Total
Median
Interquartile range
With generalization
Median
Interquartile range
4
2–10
2
1–4
3
2–10
2
1–3
0.73
0.08
No. with partial seizures 5 10 0.27
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cent fewer seizures than those in the placebo group
(95 percent confidence interval, ¡74 to 83 percent;
P=0.30). This difference, which was not statistical-
ly significant, was composed of a 41 percent reduc-
tion in the rate of partial seizures (95 percent confi-
dence interval, ¡124 to 84 percent; P=0.44) and a
significant, 67 percent reduction in the rate of sei-
zures with generalization (95 percent confidence
interval, 20 to 86 percent; P=0.01) (Table 3). Ad-
justment for base-line covariates had little effect on
these findings. The efficacy of albendazole tended
to be highest between 2 and 12 months after treat-
ment. Its lowest efficacy (¡45 percent) was observed
for the treatment of seizures with generalization
during the first month after treatment. By the sec-
ond month, however, this pattern had reversed, and
its efficacy exceeded that of placebo (Fig. 2).
When the analysis was restricted to the initial
18 months, the decrease in the rate of partial sei-
zures was 32 percent (95 percent confidence inter-
val, ¡49 to 69 percent; P=0.33) and the decrease
in the rate of seizures with generalization was 64
percent (95 percent confidence interval, 21 to 84
percent; P=0.01). When the analysis included the
first month after treatment and was extended to
month 30, there was a 42 percent reduction in the
rate of partial seizures (95 percent confidence in-
terval, ¡138 to 86; P=0.45) and a 59 percent reduc-
tion in the rate of seizures with generalization
(95 percent confidence interval, 11 to 81 percent;
P=0.03).
Thirty-two of the 57 patients in the albendazole
group (56 percent) had no seizures during the fol-
low-up period from month 2 to month 30 — a rate
that was close to that in the placebo group (30 of
the 59 patients [51 percent]). A total of 64 patients
(32 in the albendazole group and 32 in the placebo
group) had at least one seizure during the overall
trial, including the treatment period and the first
month after treatment. The distribution of the num-
ber of partial seizures was similar in the two groups
(Table 3). Most of the difference in the number of
partial seizures occurred among patients who had
had 10 or more seizures; the two patients with the
highest numbers of partial seizures (47 and 144)
were both in the placebo group. There were 46 more
seizures with generalization in the placebo group
than in the albendazole group. Patients in the pla-
cebo group had a greater tendency to have seizures
with generalization (22 of 59 patients, vs. 13 of 57
patients in the albendazole group; risk ratio, 1.63;
95 percent confidence interval, 0.91 to 2.92; P=
0.13). Six patients in the placebo group but none
of those in the albendazole group had more than
three seizures with generalization (Table 3).
Patients who had no active lesions (cysts or en-
hancing lesions) six months after treatment had
62 percent fewer seizures (95 percent confidence
interval, ¡94 to 93 percent; P=0.24) than those who
had at least one active lesion. Among those with-
out active lesions at six months, there was a slightly
greater reduction in the number of seizures with
generalization than in the number of partial sei-
zures, although the difference was not statistically
significant.
Tapering of antiepileptic drug therapy was initi-
ated in 77 patients (41 in the albendazole group and
36 in the placebo group). Partial seizures after dose
reduction or withdrawal occurred in five patients
(two in the albendazole group and three in the pla-
cebo group), and crisis with generalization occurred
in eight (two in the albendazole group and six in
the placebo group, P=0.14). Sixty-four patients (36
of 57 in the albendazole group [63 percent] and 28
of 59 in the placebo group [47 percent], P=0.13)
did not have a crisis during the six-month period
after antiepileptic-drug tapering had begun.
 
evolution of cysts
 
Follow-up MRI was performed at six months in
109 patients (55 in the albendazole group and 54 in
 
* The rash remitted immediately after phenytoin treatment 
 
was suspended.
 
Table 2. Side Effects in the Two Study Groups.
Side Effect
Albendazole
(N=57)
Placebo
(N=59) P Value
 
no. of patients
 
Neurologic
 
Partial seizures 8 5 0.51
Seizures with
generalization
2 1 0.62
Headache 32 31 0.84
Paresthesia 1 3 0.62
Paresis 1 0 0.49
Dizziness 9 4 0.21
 
Non-neurologic
 
Abdominal pain 8 0 0.006
Nausea 5 2 0.27
Diarrhea 2 0 0.24
Rash 0 1* 1.00
Other 2 1 0.62
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the placebo group). In the placebo group, most of
the noninflamed viable cysts (243 of 279 [87 per-
cent]) persisted unchanged, whereas less than half
(79 of 192 [41 percent]) did so in the albendazole
group (P<0.001; relative ratio for the persistence of
cysts with placebo, 2.12; 95 percent confidence in-
terval, 1.59 to 2.81). Cysts showing early signs of
inflammation at base line were analyzed separate-
ly, and again the proportion persisting after treat-
ment was much higher in the placebo group (in
which 29 of 59 [49 percent] persisted, vs. 10 of 48
[21 percent] in the albendazole group; P=0.013).
At six months, 21 patients in the albendazole
group were free of active lesions, as compared with
8 patients in the placebo group (P=0.007).
At two years, calcification could be detected in
62 percent of the resolved cysts in the albendazole
group, as compared with 38 percent of such cysts
in the placebo group (which resolved by natural
evolution). During follow-up, the presence of new-
ly appearing calcifications, as compared with com-
plete resolution of lesions, was not associated with
an increased number of partial seizures (P=0.4) or
seizures with generalization (P=0.7).
The use of antiparasitic drugs in neurocysticerco-
sis has been the subject of intense controversy for
more than 20 years. The introduction of praziquan-
tel in 1979
 
27
 
 was enthusiastically received,
 
28
 
 but
soon afterward, some authors claimed that there
was no need to kill a parasite that existed in good
symbiosis with the brain.
 
15,16
 
 Two retrospective
studies published in 1992 found striking differenc-
es in the evolution of seizures in favor of antipara-
sitic treatment,
 
11,12
 
 but they were criticized because
of their clear, built-in selection bias. By contrast, an
open, controlled trial published in 1995 showed no
significant differences among patients treated with
albendazole, praziquantel, or corticosteroids alone
in the evolution of seizures or even in the radiolog-
ic evolution of cysts.
 
13
 
In our controlled study, there was a significant
reduction in the rate of seizures with generalization
and a nonsignificant decrease in the rate of partial
seizures during follow-up among the patients who
received albendazole as compared with those who
received placebo, although most of these benefits
discussion
 
* CI denotes confidence interval.
† The analysis was adjusted for one to three selected base-line variables that remained at a significance level of P<0.20 after a backward-selec-
tion procedure.
‡ The overall numbers of partial seizures in the albendazole and placebo groups, respectively, were as follows: no seizures, 38 and 43; one, 
4 and 3; two, 3 and 1; three, 0 and 2; four, 3 and 0; five to nine, 5 and 3; and more than nine, 4 and 7.
§ No adjustment was performed; no variables attained a significance level of P<0.20.
¶The overall numbers of seizures with generalization in the albendazole and placebo groups, respectively, were as follows: no seizures, 44 and 
 
37; one, 6 and 8; two, 5 and 6; three, 2 and 2; four, 0 and 1; five to nine, 0 and 4; and more than nine, 0 and 1.
 
Table 3. Number of Seizures during Follow-up in the Two Study Groups.
Variable No. of Patients No. of Seizures Efficacy (95% CI)* P Value
 
Albendazole
(N=57)
Placebo
(N=59)
Albendazole
(N=57)
Placebo
(N=59) Unadjusted Adjusted† Unadjusted Adjusted†
 
percent
 
Partial seizures‡
Month 1 12 8 35 67 46 (¡141 to 88) —§ 0.42 —§
Months 2–12 18 15 100 204 49 (¡81 to 86) 43 (¡28 to 75) 0.30 0.17
Months 13–30 10 9 71 92 21 (¡249 to 82) ¡13 (¡387 to 74) 0.76 0.87
Months 2–30 19 16 171 296 41 (¡124 to 84) 34 (¡79 to 76) 0.44 0.41
Seizures with generalization¶
Month 1 7 2 7 5 ¡45 (¡681 to 73) ¡41 (¡409 to 61) 0.67 0.60
Months 2–12 8 16 12 41 70 (9 to 90) 69 (15 to 88) 0.03 0.02
Months 13–30 7 17 10 27 62 (13 to 84) 62 (8 to 84) 0.02 0.03
Months 2–30 13 22 22 68 67 (20 to 86) 67 (32 to 84) 0.01 0.003
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appeared to accrue to a relatively small number of
patients. Moreover, cysts in the brain resolved much
faster after albendazole therapy than after placebo,
as has previously been shown in treatment studies
in pigs
 
29
 
 and in uncontrolled series of patients.
 
9,30
 
This finding refutes the hypothesis that cysts natu-
rally resolve within a short period.
 
13,21
 
 An alterna-
tive, though highly unlikely, possibility is that the
short-term administration of dexamethasone may
have altered the immune equilibrium in the treat-
ment group and caused cyst destruction.
More patients in the albendazole group than in
the placebo group had seizures during treatment
and during the first month of follow-up. This effect
results from the acute perilesional inflammation
that follows exposure to parasite antigens as a re-
sult of the drug’s attack on the cyst
 
1,19
 
 and is poten-
tially preventable with the use of higher doses of
corticosteroids.
 
14
 
 The trend reversed itself after
month 2, however, and there was a persistent de-
crease in the number of seizures in the albendazole
group as compared with the placebo group. The ef-
fect was not complete, however, and there was al-
ways a background level of seizures in the treatment
group. Since not all cysts are destroyed by a course
of albendazole, seizures associated with residual le-
sions could have diluted the treatment effect seen
in the main analysis according to treatment group.
A major factor in the confusion surrounding an-
tiparasitic treatment in neurocysticercosis is the va-
riety of parasite stages that may be involved. Stage
definition is crucial for prognosis and management,
and we restricted our conclusions to patients with
viable parenchymal cysts, who constitute the ma-
jority of patients with neurocysticercosis in Latin
America.
 
31,32
 
 In contrast to other series, we includ-
ed patients who had live cysts with initial signs of
inflammation (perilesional contrast enhancement
and edema on imaging studies), provided that the
cysts had a visible liquid content. The reason for this
is that patients who have only viable, noninflamed
cysts are a minority, and we wanted the results of
our study to apply to the day-to-day clinical man-
agement of patients with neurocysticercosis. Not
all viable cysts with signs of inflammation disap-
pear over the short term. In fact, only about half of
such cysts resolved over a six-month period in the
placebo group. Subgroup analysis confirmed a sig-
nificant effect of antiparasitic therapy on the radio-
logic evolution of cysts with inflammation.
Whereas parenchymal neurocysticercosis pro-
gresses only rarely (and, when it does, progresses
slowly), most extraparenchymal forms of neurocys-
ticercosis are associated with disease progression
and hydrocephalus.
 
33
 
 The lesions in subarachnoid
cysticercosis may grow to a diameter of several cen-
timeters and cause intracranial hypertension.
 
1,6
 
Subarachnoid cysticercosis of the sylvian fissure
mimics parenchymal cysticercosis.
 
8,33
 
 Not to un-
 
Figure 2. Cumulative Frequency of Partial Seizures (Panel A) and Seizures 
with Generalization (Panel B) in the Two Study Groups during the 30 Months 
of Follow-up.
 
The interval to the left of zero on the x axis represents the 10-day treatment 
period.
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dertake antiparasitic therapy in such cases could al-
low disease progression and even risk the patient’s
life. An additional, and commonly neglected, point
of discussion is that most patients feel highly un-
comfortable leaving a parasite living in their brain.
The presence of calcifications in the brain is a
known risk factor for seizure relapse.
 
34
 
 A higher
proportion of cysts calcified in the treatment group
than in the placebo group, but there were fewer pa-
tients with seizures in the treatment group. Wheth-
er this difference in calcification reflects faster res-
olution of the lesion and shortening of the natural
evolutive process with albendazole treatment or
whether there is a true difference in the proportion
of residual calcifications after parasite death will be
evident in the long-term follow-up of our patients.
Because of globalization, many clinicians in in-
dustrialized countries who are unfamiliar with neu-
rocysticercosis are now faced with this disease.
 
3
 
They should be aware that there are cases in which
antiparasitic therapy is not indicated, because the
risks of severe side effects may outweigh the poten-
tial benefits. However, these cases are infrequent
and involve mainly patients who have massive brain
infections. In our study (which included only pa-
tients with 20 or fewer parenchymal cysts), the side
effects of active treatment were mild and included
abdominal pain and nausea, which were probably
due to the dexamethasone.
In summary, none of the major arguments
against the use of antiparasitic therapy were sup-
ported by our data. An argument against antipara-
sitic therapy could still be made, given the costs as-
sociated with the treatment and hospital admission
and the small risk of cyst growth without it. There
is also the hypothetical risk that albendazole could
leave more residual calcifications than would oth-
erwise be present, although such calcifications were
not associated with increased seizure activity in our
study. Yet the benefits of albendazole therapy in de-
creasing the numbers of seizures outweigh these
arguments, and we recommend the use of antipar-
asitic treatment as part of routine practice in the
management of parenchymal brain cysticercosis.
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